Tag - astrazeneca

 
 

ASTRAZENECA

Japan Times
WORLD / Science & Health / FOCUS
Nov 24, 2020
Decades of work, and half a dose of fortune, drove Oxford vaccine success
The Oxford vaccinologists were exhilarated on Monday when drugmaker AstraZeneca, with whom they developed the shot, announced that it could be around 90% effective.
Japan Times
WORLD / Science & Health
Oct 27, 2020
Oxford COVID-19 vaccine prompts immune response in adults, AstraZeneca says
The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among older people, British drug maker AstraZeneca PLC said on Monday.
Japan Times
JAPAN / Science & Health
Oct 3, 2020
AstraZeneca's Japanese COVID-19 vaccine trial back on, but U.S. still paused
The British drugmaker said the early-to-mid-stage trial for the vaccine against the coronavirus resumed in Japan after consultations with the national health regulator
Japan Times
WORLD / Science & Health
Sep 18, 2020
COVID-19 vaccine leaders make trial plans public in transparency push
The moves come amid increasing concern that the effort to develop a COVID-19 vaccine is becoming politicized.
Japan Times
COMMENTARY / World
Sep 11, 2020
Traders are getting smarter about the vaccine race
Investors watching the COVID-19 vaccine development process could be forgiven for thinking it's not so hard. The effort has moved extraordinarily quickly so far, and with few hiccups.
Japan Times
BUSINESS / Companies
Jul 28, 2020
Astra to pay Daiichi up to $6 billion for new cancer drug
AstraZeneca is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic.
Japan Times
BUSINESS / Companies
Jul 14, 2020
Pfizer and BioNTech coronavirus vaccine candidates on FDA fast track
The U.S.-listed shares of the German firm climbed about 15 percent, while Pfizer's stock rose about 5 percent.
Japan Times
BUSINESS / Companies
Mar 29, 2019
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain's AstraZeneca's biggest deal in recent memory give it access to the Japanese drugmaker's promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
Japan Times
JAPAN / Science & Health
Aug 8, 2017
AstraZeneca seeks Japan's first approval for hereditary cancer drug in relapsed sufferers
Olaparib, already approved in the United States and the European Union, acts against cancers in people with hereditary mutations in genes associated with breast and ovarian cancer.
EDITORIALS
May 8, 2013
Lessons from the Iressa case
The Supreme Court upholds rulings that the Japanese unit of British drug maker AstraZeneca PLC is not liable for fatal side effects of the lung cancer drug Iressa.

Longform

Japan's growing ranks of centenarians are redefining what it means to live in a super-aging society.
What comes after 100?